11 billion market value pharmaceutical companies assembled A shares! Heng Rui, Murray... It's soaring by more than 100 billion.

Today, the three major A-share indexes fell sharply, the industry sector fell across the board.
in fact, since this year, pharmaceutical stocks continued to rise, Hengrui Pharmaceuticals, Pharmaceutical Mingkang, Changchun High-tech, Huahai Pharmaceuticals and many other pharmaceutical stocks hit new highs.
as of the close of trading on July 16, Hengrui Pharmaceuticals, Changchun High-tech, and the 11 pharmaceutical stocks were worth more than 100 billion yuan.
, four of the top five pharmaceutical stocks in the market value increased by more than 100 billion yuan; Gan li Pharmaceuticals, Junshi Bio, Wantai Bio, new industries were listed this year, successfully joining the pharmaceutical stocks TOP20;
in addition, Fosun Pharma and Hualan Bio are close to the market value of 100 billion. according to
, there will be only five pharmaceutical stocks with a market capitalization of 100 billion dollars in 2019.
brokerage analysis pointed out that the short-term market rose too fast, profit close, release the reduction of pressure, strict lying at leveraged funds and other factors will make the market have some twists and turns.
pharmaceutical stock market value TOP20 Note: at the closing price of 4 sharply soaring more than 100 billion! Hengrui's share price hit a new high, and four of the top five pharmaceutical stock markets with a market value of more than $200 billion rose by more than 100 billion yuan, namely Hengrui Pharmaceuticals, Meirui Medical, Zhifei Bio and Changchun Hi-Tech.
, Hengrui Pharmaceuticals shares hit a record high, while Meirui Medical's market value has soared by more than 200 billion yuan so far this year.
Hengrui Pharmaceuticals: In November 2017, it became the first pharmaceutical stock with a market value of more than 200 billion yuan, in June 2018, with a market value of more than 300 billion yuan, in October 2019, with a market value of over 400 billion yuan, and in June this year, the market value exceeded the 500 billion mark.
market capitalisation of 511.3 billion yuan at the close of trading on July 16, up more than 40% so far this year. according to
data, since 2000, there have been Guizhou Maotai, Changchun high-tech, Hengrui Medicine and other increases are more than 300 times, of which, Guizhou Maotai is more than 400 times, Changchun high-tech super 390 times, Hengrui Pharmaceuticals ranked third.
some investors lamented that if the hang rui listed at the beginning of the purchase of 300,000, now make 100 million, small target easily achieved.
Meirui Medical: Landing a A-share in October 2018, with a market value of more than 200 billion yuan a year after listing, more than 300 billion yuan in April this year, and closing on July 15 with a market value of 423.1 billion yuan, a market value of more than 200 billion yuan compared with 2019.
market value fell to 402 billion yuan by the close of trading on July 16, second only to Heng rui, a "medical stock."
pharmaceutical new shares "kill into" TOP20! Gan Li Pharmaceuticals, Junshi Bio into the market value of the pharmaceutical stocks TOP20, Gan Li Pharmaceuticals, Junshi Bio, Wantai Bio, new industries are listed this year.
, Gan Li Pharmaceuticals, Junshi Bio among the market value of hundreds of billions of times, Wantai biological value has soared more than 20 times, the company's new crown testing products recently obtained the U.S. FDA emergency use authorization.
Gan Li Pharmaceuticals: June 29 domestic insulin leader officially landed on A-shares, 13 consecutive one-word board up and down, a signed profit of nearly 200,000 yuan, market value exceeded the scale of 100 billion.
prospectus shows that the company is mainly engaged in the restructuring of insulin analogue raw materials and injections research and development, production and sales.
2019, the company's revenue of 2.895 billion yuan, net profit of 1,167 million yuan, of which, insulin preparation revenue accounted for up to 95.10%, recombinant insulin injection is the main source of revenue.
days ago, Gan Li Pharmaceuticals issued a notice, July 16 in the form of online interaction held the 2019 annual online performance statement, the company's operating performance, corporate strategy, cash dividends and other specific circumstances to exchange.
Wantai Biologicals: April 29 landed a-share A-shares, after 26 consecutive ups and downs opened the board, has become this year's largest number of new pharmaceutical stocks, the increase has exceeded 25 times.
data show that The main business of Wantai Bio is in vitro diagnostic reagents, in vitro diagnostic instruments and vaccine research and development, production and sales, core products include HIV diagnostic reagents, viral hepatitis series diagnostic reagents.
, Wantai Bio announced that the company's new crown testing products by the U.S. FDA emergency use authorization.
it is understood that the new EUA-approved EUA-approved drug antibody rapid detection kit (colloidal gold) is used to qualitatively detect human serum, plasma (K2EDTA, heparin lithium and sodium citrate) and the total antibody of the new coronavirus in the whole blood of the vein (including IgG and IgM antibodies).
WANTAI SARS-CoV-2Ab rapid detection reagents are designed to identify individuals with a corresponding immune response to the new coronavirus, prompting recent or previous infections.
Wantai Biology said that after receiving the FDA emergency use authorization, this product can be sold in the U.S. market or in other countries that accept the FDA's emergency authorization, and has a positive impact on the company's sales and international business development.
the pharmaceutical "share god" return to the main business! Hundreds of billions of market value after the waist-sand, the return of Shanghai Leith as a head of blood products, has made a lot of money in securities investment, head medicine "share god", hundreds of billions of market value and other aura. according to
data, Shanghai Leishi's market value exceeded 100 billion yuan in 2016, with a market value of 36.9 billion yuan in December 2018 and 36.9 billion yuan in 2019.
2017 due to stock price fluctuations, Shanghai Laith's fair value change gains and losses due to securities investment and investment income were significantly lower than the previous year, with a net profit of $1.5 billion in 2018.
since then, Shanghai Laishi said that the company will no longer participate in new securities investment, the original securities investment will be in the appropriate time in the future to gradually withdraw, the future will not carry out securities investment, the company's strategy and development will focus on the main business of blood products and biological products related industries in the deep cultivation and refinement.
turned a profit in 2019, with a net profit of 608 million yuan, while the first half of this year is expected to net profit of 695 million to 745 million yuan, an increase of 68%-80% year-on-year.
market value of $65.6 billion as of the close of trading on July 16, 2020.
to this, Shanghai Laishi said that on the one hand, the company's major asset restructuring target GDS 45% equity transfer completed, the company enjoys the investment income calculated by 45% of the investment ratio since the Transfer of GDS equity, is the main reason for the substantial increase in interim results;
their own capital needs, reduce the proportion of pledge ... Pharmaceutical stocks to reduce the wind nearly half a year A-share pharmaceutical executives net reduction of shares amount TOP10July 15, Huahai Pharmaceuticals issued a shareholder reduction results announcement, shareholders Ong Zhenyu reduction plan expired, a cumulative reduction of about 13.02 million shares; After the completion, Wish Bloom reduced its total holdings by 14.9341 million shares, reducing its holdings to 1.88% of the company's total share capital, and on the same day, Huaren Pharmaceuticals announced that within 6 months after 15 trading days of the company's 9.32% shareholder Red Tower Innovation Plan, the reduction of no more than 23.6 million shares, or no more than 2% of the company's total share capital, through a centralized bidding transaction. Since this year, pharmaceutical stocks continue to rise, can be described as "taking advantage of the wind and waves", but recently there are many shareholders have issued a reduction plan, according to statistics, the year-to-date more than 100 A-share pharmaceutical companies disclosed the reduction plan.
from the scale of reduction, Jianfan Bio, Zhifei Bio, Watson Bio and other large scale of reduction, from the reasons for the reduction, including shareholders' own capital needs, repayment of loans, reduce the proportion of pledge.
brokerage analysis pointed out that the current valuation premium rate of medicine and institutional positions are standing at a high level, although facing pressure, but medicine is "the domestic demand in the new demand", the industry advantage is still very prominent.
Source: Oriental Fortune Network, listed company announcement if there are omissions, welcome to point out!